Literature DB >> 16140504

Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.

Sarojini M Sengupta, Ruby Klink, Emmanuel Stip, Trino Baptista, Ashok Malla, Ridha Joober.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16140504     DOI： 10.1016/j.schres.2005.07.024

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  10 in total

1.  The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.

Authors:  Emmanuel Stip; Stéphane Potvin
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

2.  Metabolic effects of olanzapine in patients with newly diagnosed psychosis.

Authors:  Emilio Fernandez-Egea; Brian Miller; Clemente Garcia-Rizo; Miguel Bernardo; Brian Kirkpatrick
Journal:  J Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.153

Review 3.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

Review 4.  Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.

Authors:  Cenk Tek; Suat Kucukgoncu; Sinan Guloksuz; Scott W Woods; Vinod H Srihari; Aniyizhai Annamalai
Journal:  Early Interv Psychiatry       Date:  2015-05-12       Impact factor: 2.732

5.  Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.

Authors:  Praveen Rikhari; Ashutosh Kumar; Prabhat Agrawal; Harendra Kumar
Journal:  J Family Med Prim Care       Date:  2022-05-14

Review 6.  Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Cesar González-Blanch; Ignacio Mata
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

7.  Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.

Authors:  Drigissa Ilies; Anne-Sophie Huet; Eric Lacourse; Geneviève Roy; Emmanuel Stip; Leila Ben Amor
Journal:  Can J Psychiatry       Date:  2017-07-04       Impact factor: 4.356

8.  Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.

Authors:  Karen A Graham; Hyunsoon Cho; Kimberly A Brownley; Joyce B Harp
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

9.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode.

Authors:  Celso Arango; Olalla Robles; Mara Parellada; David Fraguas; Ana Ruiz-Sancho; Oscar Medina; Arantzazu Zabala; Igor Bombín; Dolores Moreno
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-05       Impact factor: 4.785

10.  Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.

Authors:  Rakesh K Chadda; Prashanth Ramshankar; Koushik S Deb; Mamta Sood
Journal:  J Pharmacol Pharmacother       Date:  2013-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.